Total Return Level Chart

Historical Total Return Level Data

View and export this data back to 1991. Start Trial.
Date Value
October 05, 2026 733.21
October 02, 2026 742.02
October 01, 2026 741.62
September 30, 2026 765.30
September 29, 2026 757.47
September 28, 2026 759.22
September 25, 2026 795.35
September 24, 2026 803.40
September 23, 2026 809.25
September 22, 2026 811.35
September 21, 2026 805.57
September 18, 2026 792.13
September 17, 2026 796.77
September 16, 2026 781.79
September 15, 2026 781.29
September 14, 2026 801.10
September 11, 2026 788.74
September 10, 2026 800.62
September 09, 2026 815.14
September 08, 2026 817.82
September 04, 2026 835.39
September 03, 2026 851.29
September 02, 2026 859.93
September 01, 2026 831.46
August 31, 2026 806.49
Date Value
August 28, 2026 801.55
August 27, 2026 815.20
August 26, 2026 822.34
August 25, 2026 841.29
August 24, 2026 836.18
August 21, 2026 841.77
August 20, 2026 834.30
August 19, 2026 848.64
August 18, 2026 817.75
August 17, 2026 812.46
August 14, 2026 809.99
August 13, 2026 812.50
August 12, 2026 804.46
August 11, 2026 803.46
August 10, 2026 814.60
August 07, 2026 790.72
August 06, 2026 778.37
August 05, 2026 774.81
August 04, 2026 766.82
August 03, 2026 765.39
July 31, 2026 768.81
July 30, 2026 744.32
July 29, 2026 701.05
July 28, 2026 700.81
July 27, 2026 672.58

Total Return Level Definition

The total return level allows investors to view the performance of a security inclusive of both price appreciation and dividends/distributions. Total return level is seen as the most accurate calculation that produces returns consistent with most other sources.

Read full definition.

Total Return Level Range, Past 5 Years

View Total Return Level Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Return Level Benchmarks

View Total Return Level Benchmarks
Start Trial
Gilead Sciences, Inc. 211.97
Alnylam Pharmaceuticals, Inc. 219.89
Amgen, Inc. 603.43
Incyte Corp. 114.13
Vertex Pharmaceuticals, Inc. 503.50